FDA authorizes trial of stem cell eye treatment

02/16/2012 | Modern Medicine

The FDA has cleared StemCells' experimental neural stem cell therapy for use in a Phase I/II clinical trial for dry age-related macular degeneration. The open-label, dose-escalation trial will involve 16 patients. Results of a preclinical study showed the stem cell treatment can protect photoreceptors and save vision in an animal model of retinal disease.

View Full Article in:

Modern Medicine

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD